Callan Family Office LLC Lowers Stock Holdings in United Therapeutics Corporation $UTHR

Callan Family Office LLC reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 49.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,769 shares of the biotechnology company’s stock after selling 1,699 shares during the period. Callan Family Office LLC’s holdings in United Therapeutics were worth $742,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Jones Financial Companies Lllp grew its stake in United Therapeutics by 15.5% in the 3rd quarter. Jones Financial Companies Lllp now owns 611 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 82 shares during the period. Access Investment Management LLC lifted its holdings in United Therapeutics by 0.9% during the third quarter. Access Investment Management LLC now owns 7,520 shares of the biotechnology company’s stock valued at $3,152,000 after purchasing an additional 65 shares in the last quarter. UMB Bank n.a. lifted its holdings in United Therapeutics by 8.1% during the third quarter. UMB Bank n.a. now owns 1,414 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 106 shares in the last quarter. National Pension Service grew its position in shares of United Therapeutics by 29.3% in the third quarter. National Pension Service now owns 40,644 shares of the biotechnology company’s stock valued at $17,038,000 after purchasing an additional 9,202 shares during the period. Finally, Arizona State Retirement System increased its stake in shares of United Therapeutics by 0.8% during the third quarter. Arizona State Retirement System now owns 12,549 shares of the biotechnology company’s stock worth $5,261,000 after purchasing an additional 97 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. UBS Group boosted their price target on United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Wells Fargo & Company increased their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research note on Wednesday, October 29th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $509.50.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the sale, the executive vice president owned 36,781 shares of the company’s stock, valued at approximately $17,774,418.25. The trade was a 18.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the transaction, the director owned 4,190 shares of the company’s stock, valued at $2,136,900. The trade was a 19.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 542,214 shares of company stock worth $260,031,533. Insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $478.93 on Friday. The stock’s fifty day moving average is $486.76 and its two-hundred day moving average is $425.24. The firm has a market capitalization of $20.62 billion, a P/E ratio of 18.15, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.